NCT05808582尚未招募2 期
Multicenter, Single-arm, Open Clinical Study of Chidamide in Combination With Fulvestrant in HR+/HER2-advanced Breast Cancer That Has Failed Prior CDK4/6 Inhibitor Combined With Aromatase Inhibitor Therapy
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 入组人数
- 60
- 主要终点
- Progression Free Survival (PFS)
研究概览
简要总结
evaluate the efficacy and safety of chidamide combined with fulvestrant for HR+ABC
详细描述
This trial is a single-arm study. Designed to evaluate the efficacy and safety of chidamide combined with fulvestrant for HR+/HER2- advanced breast cancer that has failed previous CDK4/6 inhibitor combined with aromatase inhibitor therapy
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Age ≥ 18 years, female.
- •Both postmenopausal and premenopausal for hormone receptor positive patients, but premenopausal patients need to be given concomitant ovarian function suppression (OFS) therapy (criteria for menopause: "Judgment Criteria for Menopause after Adjuvant Therapy and Consensus on Clinical Application of Aromatase Inhibitors for Premenopausal Female Breast Cancer Patients in China").
- •Patients with HR-positive (ER-positive, PR-positive or negative) and HER2-negative breast cancer confirmed by histopathology, defined as follows.
- •Pre-enrollment disease status of non-surgically resectable locally advanced or metastatic breast cancer.
- •At least one extracranial measurable lesion as defined by RECIST V1.1 criteria or bone metastases alone.
- •Progress after previous treatment with CDK4/6 inhibitor combined with any aromatase inhibitor (after previous treatment with CDK4/6 inhibitor combined with aromatase inhibitor, you can enter the study directly or re-enter the group after chemotherapy); ; The total number of previous rescue treatments is ≤3; Previously received rescue chemotherapy ≤1 line; Time interval from the last treatment: (a) If the last treatment is endocrine therapy, it needs ≥2 weeks; (b) If the last treatment is chemotherapy, it needs ≥4 weeks;
- •ECOG PS score: 0-
- •Organ function meets the requirement.
- •expected survival ≥ 3 months.
- •Subjects of childbearing potential need to have a negative pregnancy test within 7 days prior to initiation of treatment and must use an appropriate method of contraception during treatment and for three months after completion of treatment.
- •Patients are fully informed and voluntarily sign an informed consent form.
排除标准
- •Prior treatment with any HDAC inhibitor or fulvestrant.
- •known hypersensitivity to the drug components of this trial.
- •have inflammatory breast cancer at the time of screening
- •clinical evidence or history of central nervous system metastases (CS) and/or carcinomatous meningitis, soft meningeal disease
- •inability or unwillingness to swallow medications or receive intramuscular injections
- •have gastrointestinal insufficiency or gastrointestinal disease that can significantly interfere with the absorption of study drug (e.g., uncontrolled ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection)
- •History of immunodeficiency, including testing positive for HIV, or having other acquired or congenital immunodeficiency disorders, or a history of organ transplantation.
- •other malignancies (except cured basal cell carcinoma of the skin, cervical carcinoma in situ and thyroid cancer) within the previous 5 years or concurrently
- •having undergone a major surgical operation or significant trauma within 4 weeks prior to initiation of treatment, or where the patient is expected to undergo major surgical treatment
- •Inability to understand or follow study guidelines and requirements.
- •Those who are judged by the investigator to be unsuitable for participation in this study.
研究组 & 干预措施
chidamide combined with fulvestrant
Experimental
fulvestrant
干预措施: chidamide，fulvestrant (Drug)
结局指标
主要结局
Progression Free Survival (PFS)
时间窗: 2 years
Progression-free survival estimated using Kaplan-Meier methods is defined as the time from the date of informed consent to the earlier of death or disease progression. Patients alive without disease progression are censored at the date of last disease evaluation. Progressive disease (PD) based on RECIST 1.1 is at least a 20% increase in the sum of longest diameter (LD) of target lesions taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions. Equivocal progression of non-target lesions also qualifies as PD.
次要结局
- Objective Response Rate (ORR)(2 years)
- clinical benefit rate（CBR）(2 years)
- The Number of Participants Who Experienced Adverse Events (AE)(2 years)
研究者
相似试验
Unknown
4 期
Clinical Study of Fulvestrant Combined With Chidamide in the Treatment of Hormone Receptor-positive Advanced Breast Cancer Resistant to CDK4/6 InhibitorsBreast CancerNCT05191914Liaoning Tumor Hospital & Institute20
Unknown
2 期
Chidamide Plus Chemotherapy in the Treatment of Peripheral T-cell LymphomaPeripheral T Cell LymphomaNCT02753543Ruijin Hospital33
招募中
2 期
Efficacy and Safety of Chidamide Combined With BEAM Pretreatment Regimen in Autologous Transplantation for T-cell LymphomaT Cell LymphomaNCT05367856Ruijin Hospital23
Unknown
不适用
Clinical Study of Chidamide Combined With Fulvestrant in the Treatment of Hormone Receptor-positive Advanced Breast CancerAdvanced Breast CancerNCT05047848Liaoning Tumor Hospital & Institute82
已完成
2 期
Chidamide Combined With Zimberelimab in the Treatment of Metastatic Triple-negative Breast Cancer PatientsTriple Negative Breast CancerNCT05632848Sun Yat-sen University47